These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23971497)

  • 1. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
    Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
    Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
    Cox DS; Papadopoulos K; Fang L; Bauman J; LoRusso P; Tolcher A; Patnaik A; Pendry C; Orford K; Ouellet D
    J Clin Pharmacol; 2013 Sep; 53(9):946-54. PubMed ID: 23893461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib for the treatment of melanoma.
    Alluri N; Jimeno A
    Drugs Today (Barc); 2013 Aug; 49(8):491-8. PubMed ID: 23977666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
    Chung C; Reilly S
    Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
    Ouellet D; Kassir N; Chiu J; Mouksassi MS; Leonowens C; Cox D; DeMarini DJ; Gardner O; Crist W; Patel K
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):807-17. PubMed ID: 26940938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma.
    Min MS; Yao J; Chee N; Sapadin AN; Shim-Chang H
    Cutis; 2018 Oct; 102(4):283-286. PubMed ID: 30489553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.
    Leonowens C; Pendry C; Bauman J; Young GC; Ho M; Henriquez F; Fang L; Morrison RA; Orford K; Ouellet D
    Br J Clin Pharmacol; 2014 Sep; 78(3):524-32. PubMed ID: 24606567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
    Patel U; Cornelius L; Anadkat MJ
    JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
    Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promises from trametinib in RAF active tumors.
    Sausville EA
    N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
    [No Abstract]   [Full Text] [Related]  

  • 17. Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.
    Hanft KM; Hamed E; Kaiser M; Würtemberger J; Schneider M; Pietsch T; Feige U; Meiss F; Krengel S; Niemeyer C; Hettmer S
    Pediatr Blood Cancer; 2022 Apr; 69(4):e29468. PubMed ID: 34866327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of hereditary palmoplantar keratoderma with oral trametinib.
    Song H; Dzuali F; Chi SN; Treat JR; Huang JT
    Pediatr Dermatol; 2019 Jan; 36(1):e48-e49. PubMed ID: 30548577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK drug combination approved for advanced melanoma.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.
    Liu Y; Cai P; Wang N; Zhang Q; Chen F; Shi L; Zhang Y; Wang L; Hu L
    Biochem Biophys Res Commun; 2017 Mar; 484(2):378-384. PubMed ID: 28132803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.